These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34826558)

  • 1. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
    Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.
    Dold M; Bartova L; Mendlewicz J; Souery D; Serretti A; Porcelli S; Zohar J; Montgomery S; Kasper S
    Acta Psychiatr Scand; 2018 May; 137(5):401-412. PubMed ID: 29492960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study.
    Dold M; Bartova L; Fugger G; Mitschek MMM; Kautzky A; Frey R; Montgomery S; Zohar J; Mendlewicz J; Souery D; Fabbri C; Serretti A; Kasper S
    Eur Neuropsychopharmacol; 2020 Dec; 41():70-80. PubMed ID: 33046351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.
    Bartova L; Fugger G; Dold M; Kautzky A; Fanelli G; Zanardi R; Albani D; Weidenauer A; Rujescu D; Souery D; Mendlewicz J; Montgomery S; Zohar J; Fabbri C; Serretti A; Kasper S
    J Affect Disord; 2023 Jul; 332():105-114. PubMed ID: 36958488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.
    Kato M; Chang CM
    CNS Drugs; 2013 May; 27 Suppl 1():S11-9. PubMed ID: 23709358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
    Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
    Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.
    Dold M; Kautzky A; Bartova L; Rabl U; Souery D; Mendlewicz J; Porcelli S; Serretti A; Zohar J; Montgomery S; Kasper S
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1960-1971. PubMed ID: 27816317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.
    Fugger G; Bartova L; Fabbri C; Fanelli G; Dold M; Swoboda MMM; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):715-727. PubMed ID: 34989830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study.
    Tundo A; Betro' S; Iommi M; de Filippis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study.
    Köhler S; Unger T; Hoffmann S; Steinacher B; Fydrich T; Bschor T
    Pharmacopsychiatry; 2013 Mar; 46(2):69-76. PubMed ID: 23093475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis.
    Perugi G; Pacchiarotti I; Mainardi C; Verdolini N; Menculini G; Barbuti M; Angst J; Azorin JM; Bowden CL; Mosolov S; Young AH; Vieta E;
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):825-834. PubMed ID: 31227264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
    Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A
    J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which patients with bipolar depression receive antidepressant augmentation? Results from an observational multicenter study.
    Musetti L; Tundo A; Cambiali E; Del Grande C; De Filippis R; Franceschini C; Proietti L; Betrò S; Marazziti D; Dell'Osso L
    CNS Spectr; 2022 Dec; 27(6):731-739. PubMed ID: 34505564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy.
    Kim-Romo DN; Rascati KL; Richards KM; Ford KC; Wilson JP; Beretvas SN
    J Manag Care Spec Pharm; 2016 May; 22(5):588-96. PubMed ID: 27123919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
    Morlet E; Costemale-Lacoste JF; Poulet E; McMahon K; Hoertel N; Limosin F;
    J Affect Disord; 2019 Dec; 259():210-217. PubMed ID: 31446382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study.
    McIntyre RS; Weiller E
    Adv Ther; 2015 May; 32(5):429-44. PubMed ID: 25968482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.